Evidence map›Paper›PMID 25691938›Full record

ArticleIranian journal of basic medical sciences2014

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy.

Maryam Daram, Ghodratollah Montazeri, Hadi Karimzadeh, Reza Malekzadeh, Mahmood Mahmoodi, Zahra Goodarzi, Hossein Keyvani, Shahram Mirmomen, Seyed Moayed Alavian, Michael Roggendorf and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of basic medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Maryam DaramHepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Ghodratollah MontazeriDigestive Disease Research Center, Shariati Hospital, Tehran, Iran.
Hadi KarimzadehHepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Reza MalekzadehDigestive Disease Research Center, Shariati Hospital, Tehran, Iran.
Mahmood MahmoodiDepartment of Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Zahra GoodarziHepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Hossein KeyvaniKeyvan Virology Laboratory, Tehran, Iran.
Shahram MirmomenImam Khomeini Hospital, Tehran, Iran.
Seyed Moayed AlavianBaqiyatallah Research Center for Gastroenterology and Liver Disease, Tehran, Iran.
Michael RoggendorfRobert-Koch-Haus Virchowstr.179.45147, Essen, Germany.
Seyed Mohammad JazayeriHepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRShariati Hospital · IRBaqiyatallah University of Medical Sciences · IRImam Khomeini Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objective sThe aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. MATERIALS AND

methods16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples prior to vaccination and six months after the third dose.

resultsOnly one patient lost HBsAg. 48 and 44 amino acid mutations were found before and after vaccine therapy in the vaccine group respectively, 51 of which (55.4%) occurred in immune epitopes: 5 were in B cell, 21 in T helper (Th), and 25 in cytotoxic T-lymphocyte (CTL) epitopes. In the control group, 35 and 41 amino acid substitutions were found before and after therapy, respectively. 32 (42%) of 76 amino acid changes occurred within immune epitopes. There were no differences in age, gender, and duration of chronicity in both patient and control groups in terms of the frequency and the patterns of mutations.

conclusionIn chronic carriers who already had HBsAg variants selected by the host-immune response, any immune stimulation by the vaccine had no effect on the chronic state of these patients or selected any remarkable escape mutants. Newer strategies should be considered based on third generation or the use of DNA vaccines or new adjuvants.

Indexed as

HBsAg mutantsHepatitis B immune epitopesHepatitis B vaccine

Identifiers

PMID25691938
PMCPMC4322145
OpenAlexW1551406337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.